SCHEMBL7765227

SCHEMBL7765227

Nc1nc2c(c(=O)[nH]1)NCN2C(=O)CO

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 8/20 0.47
NOS1 P29475 6/20 0.39
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
USP2 O75604 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PAH P00439 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TK1 P04183 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8896087 0.82 HPRT1 (0.46) HPRT1NOS1NOS3NOS2USP2
SCHEMBL9739844 0.78 HPRT1 (0.60) HPRT1NOS1NOS3NOS2USP2
SCHEMBL1672180 0.74 HPRT1 (0.56) HPRT1NOS1NOS3NOS2USP2
SCHEMBL3836268 0.73 HPRT1 (0.61) HPRT1NOS1NOS3NOS2TK1
SCHEMBL10917986 0.73 HPRT1 (0.52) HPRT1NOS1NOS3NOS2USP2
SCHEMBL10510121 0.73 HPRT1 (0.52) HPRT1NOS1NOS3NOS2USP2
SCHEMBL21637016 0.73 HPRT1 (0.57) HPRT1NOS1NOS3NOS2
SCHEMBL5250159 0.72 HPRT1 (0.60) HPRT1NOS1
SCHEMBL571646 0.72 HPRT1 (0.60) HPRT1NOS1TK1
SCHEMBL8149575 0.72 HPRT1 (0.60) HPRT1NOS1NOS3NOS2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912734-B2 Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) THE JOHNS HOPKINS UNIVERSITY (US) 2024-02-27 US disclosed
US-20210238213-A1 SOLID-PHASE SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING N6-(2-DEOXY-ALPHA,BETA-DERYTHROPENTOFURANOSYL)-2,6-DIAMINO-4-HYDROXY-5-FORMAMIDOPYRIMIDINE (Fapy.dG) THE JOHNS HOPKINS UNIVERSITY 2021-08-05 US disclosed
WO-2001085221-A2 ASSESSING LEVELS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE IN VIVO DUKE UNIVERSITY (US) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238213-A1 SOLID-PHASE SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING N6-(2-DEOXY-ALPHA,BETA-DERYTHROPENTOFURANOSYL)-2,6-DIAMINO-4-HYDROXY-5-FORMAMIDOPYRIMIDINE (Fapy.dG) DPYD, TYMP, RNGTT HPRT1 42/4885NOS1 4879/4885NOS3 4869/4885
US-11912734-B2 Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) DPYD, TYMP, RNGTT HPRT1 28/4885NOS1 4881/4885NOS3 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.